Lupin Divests U.S. Women’s Health Business to Evofem for $84 Million

On July 15, 2024, Lupin Limited, a global pharmaceutical company, announced via a stock exchange filing that it had divested its U.S. Commercial Women’s Health Specialty Business to Evofem Biosciences, Inc., a U.S. biopharmaceutical company dedicated to Women’s Health.

Lupin’s U.S. Women’s Health Specialty Business primarily focuses on commercialising SOLOSEC® (secnidazole) 2g oral granules, an FDA-approved single-dose antimicrobial agent. SOLOSEC® offers a complete course of therapy for treating bacterial vaginosis (BV) and trichomoniasis, two prevalent sexual health infections.

According to the terms of the deal, Lupin stands to receive a potential total consideration of up to USD 84 million, contingent on future milestones.

This strategic move allows Lupin to streamline its focus while enabling Evofem to enhance its portfolio and strengthen its Women’s Health sector position. The transaction underscores the ongoing consolidation in the pharmaceutical industry, which aims to optimise resources and focus on core competencies.

Speaking of this development, the President of Global Corporate Development at Lupin, Dr Fabrice Egros, said, “We are very pleased to divest our U.S. Commercial Women’s Health Specialty business, including SOLOSEC®, to Evofem. This divestment is another step in aligning our U.S. speciality business with our strategic plan to build our speciality business in therapeutic areas where we have building blocks of synergy. These include respiratory and neurological diseases.”

“The acquisition of this commercial business aligns with and advances our mission to improve access to innovative and differentiated options that impact women’s daily lives. SOLOSEC is a commercially attractive, single-dose oral antibiotic that addresses two pervasive sexual health infections. We can now fully leverage our commercial infrastructure, maximise our strong physician relationships, and re-launch an asset with tremendous growth potential,” said Saundra Pelletier, Chief Executive Officer of Evofem.

About Lupin Ltd

Lupin is an innovation-driven transnational pharmaceutical company. The company develops and commercialises a diverse range of branded and generic formulations, Active Pharmaceutical Ingredients (API) and biotechnology products. Lupin operates in over 100 markets, including India, the U.S., South Africa, the Asia Pacific (APAC) region, the Middle East, Europe, and Latin America (LATAM).

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.